收费全文 | 2322篇 |
免费 | 105篇 |
国内免费 | 4篇 |
耳鼻咽喉 | 57篇 |
儿科学 | 48篇 |
妇产科学 | 34篇 |
基础医学 | 225篇 |
口腔科学 | 29篇 |
临床医学 | 164篇 |
内科学 | 584篇 |
皮肤病学 | 50篇 |
神经病学 | 145篇 |
特种医学 | 84篇 |
外科学 | 402篇 |
综合类 | 55篇 |
一般理论 | 2篇 |
预防医学 | 243篇 |
眼科学 | 25篇 |
药学 | 134篇 |
中国医学 | 4篇 |
肿瘤学 | 146篇 |
2023年 | 19篇 |
2022年 | 33篇 |
2021年 | 96篇 |
2020年 | 41篇 |
2019年 | 56篇 |
2018年 | 69篇 |
2017年 | 49篇 |
2016年 | 60篇 |
2015年 | 57篇 |
2014年 | 70篇 |
2013年 | 88篇 |
2012年 | 191篇 |
2011年 | 204篇 |
2010年 | 118篇 |
2009年 | 106篇 |
2008年 | 125篇 |
2007年 | 155篇 |
2006年 | 139篇 |
2005年 | 134篇 |
2004年 | 114篇 |
2003年 | 104篇 |
2002年 | 91篇 |
2001年 | 34篇 |
2000年 | 34篇 |
1999年 | 36篇 |
1998年 | 9篇 |
1997年 | 17篇 |
1996年 | 7篇 |
1995年 | 6篇 |
1994年 | 9篇 |
1993年 | 7篇 |
1992年 | 11篇 |
1991年 | 9篇 |
1990年 | 11篇 |
1989年 | 22篇 |
1988年 | 12篇 |
1987年 | 9篇 |
1986年 | 13篇 |
1985年 | 10篇 |
1983年 | 3篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1975年 | 5篇 |
1974年 | 4篇 |
1973年 | 5篇 |
1972年 | 2篇 |
Purpose
The PPAR-alpha agonists (fibrates) are commonly used in the treatment of dyslipidemia. It has been hypothesized that the cardio-protective effects of fibrates are partially due to immunomodulatory effects. However, there is a paucity of data regarding the effect of fibrates on neutrophilic chemokines such as epithelial neutrophil activating protein (ENA-78) and interleukin (IL)-8. We investigated the influence of fenofibrate on IL-1β-stimulated production of ENA-78 and IL-8 from human endothelial cells (HUVECs). 相似文献Transscleral controlled cyclophotocoagulation (COCO) is a transscleral 810-nm diode laser cyclophotocoagulation that automatically adjusts the applied laser energy utilizing an optical feedback loop. The present study investigates the influence of pseudoexfoliation (PEX) on the efficacy of COCO in a Caucasian study population.
MethodsRetrospective data from 130 consecutive eyes were analyzed during a 2-year follow-up. Baseline characteristics, intraocular pressure (IOP), number of IOP-lowering medications, visual field, best-corrected visual acuity (BCVA), and secondary surgical interventions (SSI) were analyzed. The primary endpoint was IOP reduction at M24 compared to baseline, and the secondary endpoints were IOP course, reduction of IOP-lowering medications, surgical success, and IOP-lowering SSIs stratified by PEX and baseline IOP.
ResultsIOP reductions of −35, −39, −25, −25, −23, −34, and −36% could be achieved from baseline to D1, W1, M1, M3, M6, M12, and M24 (all p < 0.001), respectively, while there was a significant overall reduction over time (p < 0.001) in the number of topical IOP-lowering medications postoperatively. The proportion of eyes requiring additional systemic IOP-lowering medication reduced from 31 to 0% at M24 (p = 0.025). Eyes without PEX and IOP < 30 mmHg at baseline had the lowest risk for IOP-lowering SSIs (p < 0.03). BCVA dropped at M12 (0.25 [95% CI: 0.12–0.38]), and the drop persisted during the following 12 months.
ConclusionThe present study demonstrates a midterm IOP-lowering effect after COCO while reducing the burden for topical and systemic IOP-lowering medications. Patients without PEX and IOP < 30 mmHg have a lower risk of SSI. The procedure per se cannot be excluded as causative for the decreased postoperative BCVA. Further prospective investigations are suggested.
相似文献